Communication

Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy†

  1. Zhuang Liu1,2,‡,
  2. Alice C. Fan3,‡,
  3. Kavya Rakhra3,
  4. Sarah Sherlock1,
  5. Andrew Goodwin1,
  6. Xiaoyuan Chen4,
  7. Qiwei Yang3,
  8. Dean W. Felsher3,
  9. Hongjie Dai1

Article first published online: 16 SEP 2009

DOI: 10.1002/anie.200902612

Issue

Angewandte Chemie International Edition

Angewandte Chemie International Edition

Volume 48, Issue 41, pages 7668–7672, September 28, 2009

Additional Information

How to Cite

Liu, Z., Fan, A., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., Yang, Q., Felsher, D. and Dai, H. (2009), Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy. Angewandte Chemie International Edition, 48: 7668–7672. doi: 10.1002/anie.200902612

Author Information

  1. 1

    Department of Chemistry, Stanford University, Stanford, CA 94305 (USA)

  2. 2

    Functional Nano & Soft Materials Laboratory (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123 (China)

  3. 3

    Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305 (USA)

  4. 4

    Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305 (USA)

  1. ‡

    These authors contributed equally to this work.

  1. †

    This work was supported in part by the National Institutes of Health (NIH)–National Cancer Institution (NCI) grants R01 CA135109-01 (H.D.), 1R01 CA89305-01A1 (D.W.F.), 3R01 CA89305-0351 (D.W.F.), 1R01 CA105102 Lymphoma Program Project (D.W.F.), NIH-NCI In Vivo Cellular and Molecular Imaging Center Grant P50 (D.W.F.), NIH–NCI Center for Cancer Nanotechnology Excellence Focused on Therapeutic Response at Stanford (H.D.), Burroughs Wellcome Fund (D.W.F.), the Damon Runyon Foundation (D.W.F.), the Leukemia and Lymphoma Society (D.W.F., A.C.F.), a Stanford Bio-X Initiative Grant (H.D., D.W.F.), an Enscyse grant (H.D.), and a Stanford Graduate Fellowship (Z.L.).

Publication History

  1. Issue published online: 23 SEP 2009
  2. Article first published online: 16 SEP 2009
  3. Manuscript Revised: 21 JUL 2009
  4. Manuscript Received: 15 MAY 2009

Funded by

  • National Institutes of Health (NIH)–National Cancer Institution (NCI). Grant Numbers: R01 CA135109-01, 1R01 CA89305-01A1, 3R01 CA89305-0351, 1R01 CA105102

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (579K)

Keywords:

  • cancer;
  • drug delivery;
  • nanotubes;
  • pi interactions;
  • nano-biotechnology

Graphical Abstract

Thumbnail image of graphical abstract

The evidence is stacking up: Many therapeutic advantages such as prolonged circulation in the blood, increased tumor drug uptake, enhanced therapeutic efficacy, and markedly reduced toxic side effects are provided by a carbon nanotube based chemotherapeutic formulation (see picture). In this system, doxorubicin (DOX) is loaded onto the sidewalls of functionalized single-walled carbon nanotubes by supramolecular π–π stacking.

View Full Article with Supporting Information (HTML) Get PDF (579K)